Candel Therapeutics, Inc. (CADL) Stock Price & Analysis
Candel Therapeutics, Inc. (CADL) rose 2.00% to USD 8.67 as of June 10, 2026 at 03:05 UTC, according to Nexqual real-time market data.
CADL last closed at USD 8.5; the session ranged USD 8.27–8.85 on volume of 1,558,956 shares. Market capitalization is $635.25M, with a 52-week range of USD 4.35–9.57 (NGM). Source: Nexqual, June 10, 2026 at 03:05 UTC.
Key Statistics (as of June 10, 2026 at 03:05 UTC)
| Price | USD 8.67 |
|---|---|
| Change | ▲ 2.00% (up) |
| Previous Close | USD 8.5 |
| Open | USD 8.55 |
| Day Range | USD 8.27 – 8.85 |
| 52-Week Range | USD 4.35 – 9.57 |
| Volume | 1,558,956 shares |
| Market Cap | $635.25M |
| Exchange | NGM |
Technical Analysis (CADL)
Nexqual's technical model rates CADL "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 03:05 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 57.47 (neutral) |
| vs SMA50 | Above (USD 7.05) |
| MACD | 0.42 (positive) |
Analyst Ratings (CADL)
Wall Street analysts rate CADL "Strong Buy" based on 8 analysts, with a mean price target of USD 19.63 (range USD 9–29), per Nexqual as of June 10, 2026 at 03:05 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 19.63 |
| High Target | USD 29 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 8 / 1 / 0 |
Earnings (CADL)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.26 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.14 vs est -0.33 ▲ beat |
| 2025-12-31 | USD -0.29 vs est -0.24 ▼ miss |
| 2025-09-30 | USD -0.23 vs est -0.17 ▼ miss |
| 2025-06-30 | USD -0.2 vs est -0.18 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:05 UTC.
Financials & Fundamentals (CADL)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -51.17% |
| Debt / Equity | 35.7 |
| Current Ratio | 28.05 |
| Total Cash | $194.83M |
| Total Debt | $49.27M |
| Free Cash Flow | $-37.90M |
Source: Nexqual, June 10, 2026 at 03:05 UTC.
Financial Health Score (CADL)
Nexqual rates Candel Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:05 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $195M cash vs $49M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$48M |
| Efficiency | Critical — ROE -51%, ROA -23.6% |
Ownership (CADL)
| Insider Ownership | +15.78% |
|---|---|
| Institutional Ownership | +59.72% |
| Shares Outstanding | 73.27M |
| Float | 56.78M |
| Short % of Float | +25.18% |
Source: Nexqual, June 10, 2026 at 03:05 UTC.
Leadership (CADL)
Candel Therapeutics, Inc. is led by Paul-Peter Tak FOCIS (age 64), President, CEO & Director, per Nexqual as of June 10, 2026 at 03:05 UTC.
| President, CEO & Director | Paul-Peter Tak FOCIS (age 64) |
|---|---|
| Senior VP, CFO, Treasurer & Secretary | Charles Schoch (age 40) |
| Chief Scientific Officer | Francesca Barone (age 47) |
Major Backers & Investors (CADL)
Notable institutional backers of Candel Therapeutics, Inc. include FMR, LLC, Fidelity, RTW Investments LP, according to Nexqual as of June 10, 2026 at 03:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 15% |
| Fidelity | 13.33% |
| RTW Investments LP | 8.76% |
| Acorn Capital Advisors, LLC | 4.77% |
| Saturn V Capital Management LP | 3.95% |
| Portolan Capital Management, LLC | 3.95% |
| Vestal Point Capital, LP | 1.54% |
| Millennium Management | 1.45% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.65% |
| BlackRock | 6.24% |
Source: Nexqual, June 10, 2026 at 03:05 UTC.
From Candel Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- We have also designed additional novel viral immunotherapy candidates using our proprietary enLIGHTEN™ Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors.
- The FDA granted Fast Track Designation for the use of aglatimagene for the treatment of localized, primary prostate cancer in combination with radiation therapy to improve the local control rate. o The primary goal of curative treatment for localized prostate cancer is complete tumor eradication, as outlined by National Comprehensive Cancer Network (NCCN) guidelines.
- Therefore, this study aimed to assess whether adding aglatimagene plus valacyclovir to standard of care (SoC) radiotherapy could improve disease-free survival (DFS) in patients pursuing curative treatment, a primary endpoint established in the SPA with the FDA.
- Key attributes of the enLIGHTEN™ Discovery Platform include: ▪ Strong focus on human biology, including deep phenotyping of human tumors, to increase probability of success ▪ Data driven selection of the payload.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IMRX | Immuneering Corporation | USD 4.03 | ▼ 5.62% |
| INAB | IN8bio, Inc. | USD 1.45 | ▲ 0% |
| CING | Cingulate Inc. | USD 4.65 | ▲ 3.45% |
| JANX | Janux Therapeutics, Inc. | USD 13.62 | ▲ 1.95% |
| TPST | Tempest Therapeutics, Inc. | USD 1.27 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:05 UTC. This page is informational and not investment advice.